Prostate Cancer
Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
Published in Health Business Week, January 4th, 2008
Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) today commented on the announcement by Bayer Healthcare that they would discontinue marketing their product Viadur(R) (leuprolide acetate implant), which is indicated for the palliative treatment of advanced prostate cancer. As a result of this announcement, Indevus' product VANTAS(R) (histrelin implant) will be the only 12-month implant for the palliative treatment of advanced prostate cancer. Indevus remains committed to providing patients and physicians effective options for the treatment of advanced prostate cancer.
"Indevus is firmly committed to providing continuity of care for current Viadur patients," stated Kurt W....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2008-01-04)
More Articles from Health Business Week
- 4SC Ag
4SC AG: Management Board and Supervisory Board Publish Statement on the Mandatory Offer of Santo Holding - A Complaint Free World
A 'Happy New You' in the New Year - A.P. Pharma, Inc.
A.P. Pharma Announces Chief Executive Officer Succession Plan - A.P. Pharma, Inc.
A.P. Pharma Stockholders Approve 2007 Equity Incentive Plan and Amendment to 1997 Employee Stock Purchase Plan - Abbott
Abbott Declares 336th Consecutive Quarterly Dividend - Abbott
Abbott to Present at JP Morgan Healthcare Conference - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
